Welcome to our dedicated page for Nutriband Warrant news (Ticker: NTRBW), a resource for investors and traders seeking the latest updates and insights on Nutriband Warrant stock.
Nutriband Inc. is a health and pharmaceutical company based in Oviedo, Florida, primarily focusing on transdermal and topical technologies for product development. Their lead product, AVERSA technology, works to prevent drug abuse and diversion, especially opioids. Most revenue is generated from consumer transdermal and coated products. Nutriband is progressing towards a 505(b)(2) NDA submission to the FDA for marketing approval of AVERSA™ Fentanyl in Q1 2025.
The recent private placement of $8.4 million will fund the commercial development of AVERSA Fentanyl for NDA filing. Nutriband is working on the commercial scale-up and pivotal clinical study for FDA approval. AVERSA technology aims to revolutionize opioid patches with abuse-deterrent properties, making them safer and more effective.
By utilizing their proprietary AVERSA™ abuse-deterrent technology, Nutriband is dedicated to preventing drug abuse and misuse while ensuring accessibility to those in need. With a focused approach on innovation and safety, Nutriband is positioned to make a significant impact in the pharmaceutical industry.
Rhea-AI Summary
Nutriband Inc. announces the development of AVERSA™ Fentanyl, an abuse-deterrent fentanyl transdermal patch, through a 505(b)(2) New Drug Application (NDA) pathway. Partnering with Kindeva Drug Delivery, Nutriband aims to revolutionize the opioid market by incorporating their AVERSA™ technology into FDA-approved transdermal fentanyl patches. The NDA submission will be based on a single Phase 1 human abuse potential clinical study, eliminating the need for Phase 2 or 3 trials. This streamlined regulatory process could lead to expedited FDA review, potentially making AVERSA™ Fentanyl the first abuse-deterrent patch approved globally. Market analysis projects peak annual US sales of $80 million to $200 million for AVERSA™ Fentanyl, tapping into the $22.8 billion global opioid market.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
90.57%
Tags
-
Rhea-AI Summary
Nutriband Inc. presents data on transdermal patch abuse and accidental pediatric exposure at the 2024 AAPM Annual Meeting. The company's AVERSA™ technology aims to provide safer abuse-deterrent transdermal patches for opioid and stimulant drugs, addressing a critical unmet need in the market.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
40.4%
Tags
-
Rhea-AI Summary
Nutriband Inc. announces data on transdermal patch abuse and accidental exposure to be presented at the 2024 AAPM Annual Meeting. The company collaborated with RMPDS to determine abuse rates in the US.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
News
Rhea-AI Summary
Nutriband Inc. (NTRB) is set to present at The Microcap Conference in Atlantic City from January 30th to February 1st. CEO Gareth Sheridan will deliver two presentations and address questions. The company aims to showcase its potential to investors and traders.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-27.88%
Tags
-
Rhea-AI Summary
Nutriband Inc. CEO Gareth Sheridan published a letter to shareholders outlining the company's achievements in 2023 and targets for 2024. The company made significant strides in developing transdermal pharmaceutical products, securing new IP, and signing a commercial development and clinical supply agreement with Kindeva Drug Delivery for AVERSA Fentanyl, estimated to potentially reach peak annual sales of $80M - $200M. The company also reported strong revenue growth in 2023 and aims to expand its revenue opportunities through marketing initiatives and new product launches in 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.94%
Tags
-
Rhea-AI Summary
Nutriband Inc. (NTRB) announced a commercial development and clinical supply agreement for their lead product, Aversa™ Fentanyl, with Kindeva Drug Delivery. The agreement aims to support a New Drug Application (NDA) with the FDA, replacing a previous feasibility agreement. Aversa™ Fentanyl is estimated to have the potential to reach peak annual US sales of $80M - $200M.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
Rhea-AI Summary
Nutriband Inc. (NTRB) launches Heating and Cooling Kinesiology Tape under AI Tape brand, offering pain-relieving ingredients for temporary relief of minor aches and pains. The product is the second launch this year, manufactured in the USA at Nutriband's facility in North Carolina, and available for purchase on Amazon and Activeintell.com.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-37.63%
Tags
-
Rhea-AI Summary
Nutriband Inc. (NASDAQ:NTRB)(NASDAQ:NTRBW) announces supplier agreement with KT Tape, a market leading kinesiology tape company, for a new line of specialized KT tape. The agreement showcases Nutriband's manufacturing capabilities and positions the company to develop innovative new product technologies with one of the world's largest brands, KT Tape.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary
Nutriband completes market assessment and commercialization strategy for Aversa Buprenorphine transdermal system.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
Rhea-AI Summary
Nutriband Inc. expands patent portfolio for AVERSA™ transdermal abuse deterrent technology, potentially reaching peak annual U.S. sales of $80M - $200M.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.93%
Tags
FAQ
What is the current stock price of Nutriband Warrant (NTRBW)?
The current stock price of Nutriband Warrant (NTRBW) is $1.56 as of December 18, 2024.
What is Nutriband Inc.'s primary focus?
Nutriband Inc. is primarily focused on transdermal and topical technologies for product development, with a specific emphasis on preventing drug abuse and diversion.
What is AVERSA technology?
AVERSA technology is Nutriband Inc.'s lead product designed to prevent the abuse, misuse, diversion, and accidental exposure of drugs with abuse potential, particularly opioids.
What is the recent achievement of Nutriband Inc.?
Nutriband Inc. closed an $8.4 million private placement to fund the commercial development of AVERSA Fentanyl, aimed at advancing towards FDA approval and revolutionizing opioid patches with abuse-deterrent properties.
What is Nutriband Inc.'s goal in the pharmaceutical industry?
Nutriband Inc. aims to utilize its proprietary AVERSA™ abuse-deterrent technology to enhance the safety and effectiveness of transdermal drugs while maintaining accessibility for patients in need.
How is Nutriband Inc. striving for innovation?
Through a focused approach on innovation and safety, Nutriband is dedicated to developing solutions that prevent drug abuse and misuse, contributing to a safer pharmaceutical industry.
Nutriband Inc. Warrant
Nasdaq:NTRBW
NTRBW Rankings
NTRBW Stock Data
11.11M
Biotechnology
Orthopedic, Prosthetic & Surgical Appliances & Supplies
United States of America
ORLANDO